Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

INTRODUCTION: Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based on observational data from t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Risk Manag Healthc Policy
Autors principals: Canonica, Giorgio Walter, Colombo, Giorgio Lorenzo, Rogliani, Paola, Santus, Pierachille, Pitotti, Claudia, Di Matteo, Sergio, Martinotti, Chiara, Bruno, Giacomo Matteo
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6986414/
https://ncbi.nlm.nih.gov/pubmed/32158289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RMHP.S211321
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars